Cumberland Pharmaceuticals Partners with Premier to Enhance Access to Vibativ® Antibiotic Treatment

Cumberland Pharmaceuticals Expands Access to Vibativ® through National Agreement

Cumberland Pharmaceuticals Inc., a Nashville-based specialty pharmaceutical company, has recently secured a significant partnership with Premier, Inc. that promises to enhance access to its antibiotic, Vibativ® (telavancin). Effective October 1, 2025, this agreement allows Premier's extensive network—comprising approximately 4,350 U.S. hospitals and 325,000 healthcare providers—to benefit from pre-negotiated pricing options for Vibativ. The initiative aims to improve treatment accessibility for severe Gram-positive infections, a pressing concern in healthcare settings.

The strategic addition of Vibativ to Premier's offerings introduces two packaging options designed to meet varying clinical needs. The standard 12-vial carton is tailored for hospitals managing higher patient volumes, while the newly introduced 4-vial Starter Pak serves as a cost-effective option for initiating therapy and managing inventory. This dual-approach not only provides flexibility for healthcare providers but also addresses the challenges associated with treating complex infections, such as hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) and complicated skin and skin structure infections (cSSSI). A.J. Kazimi, CEO of Cumberland Pharmaceuticals, emphasizes that this collaboration reflects the company's commitment to offering practical and economical solutions for clinicians facing demanding treatment scenarios.

By partnering with Premier, Cumberland Pharmaceuticals demonstrates its dedication to improving healthcare outcomes while simultaneously reducing costs for providers. The agreement is poised to facilitate better patient care, particularly for those requiring urgent and effective antibiotic treatment. Through this partnership, healthcare providers can more easily access Vibativ, thereby enhancing their capacity to manage severe infections effectively. For further information on ordering and medical inquiries, interested parties are encouraged to visit the Vibativ website or reach out to Cumberland Pharmaceuticals' Medical Affairs team.

In addition to the new agreement with Premier, Cumberland Pharmaceuticals continues to focus on innovative solutions within the specialty pharmaceutical sector. The company’s proactive approach to addressing healthcare needs showcases its long-term vision and commitment to enhancing treatment options for healthcare providers and their patients. As antibiotic resistance remains a critical issue, the accessibility of effective treatments like Vibativ becomes increasingly vital in the fight against drug-resistant infections.